In the past week, between June 13 and 16, 2022, the MTM Team left for San Diego (California, USA) to participate in the latest edition of BIO International Convention, a must-attend event for life sciences experts and practitioners – a sector in which the U.S. is the world leader, occupying 58 percent of the market with a turnover of 137.6 billion in 2021.

At the fair, the MTM Team, within the European delegation, headed by EIC, Overseas Trade Fairs 2.0, had the opportunity to attend live demonstrations, coming into contact with machines, cutting-edge technological solutions in the BioTech sector, and the latest medical products and devices.With reference precisely to the MedTech sector, MTM presented its latest medical R&D project, ROG (Real Organ Generation).

Visitors were offered the opportunity to experience our high-tech software platform, characterized by Virtual Reality and Artificial Intelligence technologies, aimed at not only educational and training paths, but also for diagnosis and surgical simulation.

The “testers,” in fact, were given the opportunity to immerse themselves in a 360-degree virtual environment in which they could interact with the organs and instruments in the operating room. It was enough to don a helmet and grab a pair of triggers, and then begin operating in a virtual environment as real surgeons equipped with scalpels and surgical scissors.

As for the more purely entrepreneurial side, the event proved to be an excellent networking opportunity: in fact, the event brought together more than 16,000 “innovators” including engineers, designers and manufacturers from across the medical and health care industry, thus becoming an important driving force for the exploration of new ideas and the discovery of the latest technologies, including innovative products and services for the medical and health care tout court.

Ultimately, BIO 2022 proved to be an excellent opportunity for MTM to learn about foreign developments in the creation of new production facilities that meet current needs, as well as to build new possible collaborative relationships in the joint development of future R&D projects.